Screener
Cogent Biosciences, Inc. COGT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | (10,200) | (8,658) |
| Operating lease liability | (422) | (376) |
| Other liabilities | 29 | 5 |
| Net cash used in operating activities | (86,883) | (66,511) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (449) | (547) |
| Purchases of marketable securities | (133,839) | — |
| Maturities and sales of marketable securities | 97,831 | 69,926 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s operating cash flow?
- Cogent Biosciences, Inc. (COGT) reported operating cash flow of -$86.88M in Q1 2026.
- How has Cogent Biosciences, Inc.'s operating cash flow changed year-over-year?
- Cogent Biosciences, Inc.'s operating cash flow decreased by 30.6% year-over-year, from -$66.51M to -$86.88M.
- What is the long-term trend for Cogent Biosciences, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s operating cash flow has grown at a 45.6% compound annual growth rate (CAGR), from -$58.76M to -$264.44M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Cogent Biosciences, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude